Prescription drug formularies in managed care: Concerns for the elderly population

Clinical Therapeutics

Volumn 20, Issue 6, 1998, Pages 1277-1291

  Gross, David J ^a  

^a AARP   (United States)

Author keywords

Elderly; Formularies; Managed care; Prescription drugs

Indexed keywords

DRUG;

CONFERENCE PAPER; DRUG COST; DRUG FORMULARY; ECONOMICS; ELDERLY CARE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH INSURANCE; MANAGED CARE; PHARMACEUTICAL CARE; PRESCRIPTION; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 0032418565     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80122-7     Document Type: Conference Paper

References (28)

1. 1. Kozma CM, Reeder E, Lingle E. Economic impact of cost-containment strategies in third party programmes in the U.S., Part II. PharmacoEconomics. 1993;4: 187-202.
2. 2. National Pharmaceutical Council (NPC). Perspectives on Restrictive Drug Formularies. Reston, VA: National Pharmaceutical Council; 1994.
3. 3. Novartis Pharmaceuticals Corporation. Novartis Pharmacy Benefit Report: 1998 Trends & Forecasts. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 1998.
4. 4. Drake D, Uhlman M. Making Medicine, Making Money. Kansas City, MO: Andrews and McNeel; 1993.
5. 5. American Association of Retired Persons. Older Americans and Prescription Drugs: Utilization, Expenditures and Coverage. Washington, DC: AARP Public Policy Institute, Issue Brief No. 9; September 1991.
6. 6. Guenther G. Prescription Drug Prices: Should the Federal Government Regulate Them? Washington, DC: Congressional Research Service Issue Brief IB92097; 1994.
7. 7. Inside the Industry - Rite Aid: To Buy Lilly's Pharmacy Benefits for $1.5 B [online]. Amer HealthLine. Available at: http://www.cloakroom.com/pub/healthline/ db2/1998/11/m981117.6.html.
8. 8. Avorn J. Medication use and the elderly: Current status and opportunities. Health Aff. 1995;14:276-286.
9. 9. Kreling DH, Lipton HL, Collins T, Hertz K. Assessment of the Impact of Pharmacy Benefit Managers. Report for the Health Care Financing Administration, Master Contract HCFA-95-023/PK. Madison, WI: Center for Health Systems Research and Analysis, University of Wisconsin; 1996.
10. 10. Gross DJ, Ratner J, Perez J, Glavin S. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom. Health Care Finance Rev. 1994;15:127-140.
11. 11. US General Accounting Office. Prescription Drugs: Companies Typically Charge More in the United States than in Canada. Washington, DC: GAO/HRD-92-110; 1992.
12. 12. Grabowski H, Mullins CD. Pharmaceutical benefit management: Cost-effectiveness analysis and drug formulary decisions. Soc Sci Med. 1997;45:535-544.
13. 13. Lyles CA, Luce BR, Rentz AM. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Soc Sci Med. 1997;45:511-521.
14. 14. Lipton HL, Lee PR. Drugs and the Elderly: Clinical, Social, and Policy Perspectives. Stanford, CA: Stanford University Press; 1988.
15. 15. Kessler D, Rose JL, Temple RJ, et al. Therapeutic-class wars - Drug promotion in a competitive marketplace. NEJM. 1994; 331:1350-1353.
16. 16. Office of the Inspector General (OIG), US Department of Health and Human Services. Experiences of Health Maintenance Organizations with Pharmacy Benefits Management Companies. Document No. OEI-01-95-00210. Washington, DC: OIG; April 1997.
17. 17. US General Accounting Office (GAO). Pharmacy Benefits Managers: Early Results on Ventures with Drug Manufacturers. Washington, DC: GAO/HEHS-96-45; November 1995.
18. 18. Gross DJ. Issues Related to the Federal Government Drug Payment Policies in the Reformed Health Care Environment. Report for the Health Care Financing Administration, Contract 500-93-0031. Washington, DC: KPMG Peat Marwick LLP; 1995.
19. 19. Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: Results from the managed care outcomes project. Am J Managed Care. 1996;2:253-264.
20. 20. Soumerai S, Ross-Degnan D. HMO formularies and care costs. Lancet. 1996;347:1264.
21. 21. Gibaldi M. Drug formularies and health care costs: In God we trust, the rest must show data. The University of Washington, Pharmaceutical Outcomes Research & Policy Program Report 2.2, Department of Pharmacy. Seattle, WA: The University of Washington, Spring 1996;1-3.
22. 22. Schulman K, Rubenstein LE, Abernethy DR, et al. The effect of pharmacy benefit managers: Is it being evaluated? Ann Intern Med. 1996;124:906-913.
23. 23. Green M. Pharmaceutical Payola: How Secret Commercial Deals Are Dictating Your Next Prescription and Harming Your Health. New York: New York City Public Advocate; 1997.
24. 24. Freudenheim M. Pharmaceutical giant is buying operator of drug benefit plans. New York Times. July 12, 1994:A1.
25. 25. Rucker TD, Schiff G. Drug formularies: Myths-in-formation. Med Care. 1990;28: 928-942.
26. 26. Keating P. Why you may be getting the wrong medicine. Money. June 1997; 142-157.
27. 27. Stock JA, Kofoed L. Therapeutic interchange of fluoxetine and sertraline: Experience in a clinical setting. Am J Hosp Pharm. 1994;51:2279-2281.
28. 28. American Pharmaceutical Association. Guidelines for Medication Incentive Programs. Washington, DC: American Pharmaceutical Association; May 1995.